(Q34626963)

3 August 2017

1 reference

title

Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women (English)

1 reference

3 August 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

31638

metastatic breast cancer

1 reference

2

Kate McKeage

1 reference

3 August 2017

Jamie D Croxtall

1

1 reference

3 August 2017

publication date

1 February 2011

1 reference

3 August 2017

1 reference

3 August 2017

volume

71

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

363-380

1 reference

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Oestrogen exposure and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

The multifaceted mechanisms of estradiol and estrogen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Estrogen receptors: how do they signal and what are their targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Sex steroid-producing enzymes in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant (Faslodex): current status in the therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

What clinicians need to know about antioestrogen resistance in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Endocrine therapy in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Sex hormones in postmenopausal women with breast cancer on tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Letrozole : in postmenopausal hormone-responsive early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Endocrine treatment options for advanced breast cancer--the role of fulvestrant

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Exemestane: a review of its use in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

The future of fulvestrant ("Faslodex").

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11204810-000000000-00000

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme

21 January 2018

1 reference

12 December 2020

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

12 December 2020

Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.

1 reference

12 December 2020

Endocrine therapy of advanced disease: analysis and implications of the existing data.

1 reference

12 December 2020

Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells

1 reference

12 December 2020

Therapeutic options in the management of metastatic breast cancer.

1 reference

12 December 2020

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

1 reference

12 December 2020

Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen.

1 reference

12 December 2020

Steroidal pure antioestrogens

1 reference

12 December 2020

The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.

1 reference

12 December 2020

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer

1 reference

12 December 2020

Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer

1 reference

12 December 2020

Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780

1 reference

12 December 2020

Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients

1 reference

12 December 2020

Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.

1 reference

12 December 2020

A potent specific pure antiestrogen with clinical potential

1 reference

12 December 2020

Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre

1 reference

12 December 2020

10.2165/11204810-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1014582953

0 references

1 reference